This information comes from Christina
. She was asked to provide us with some information from the LLS. Thank you Christina. From an e-mail directly from the Exec Director of the Nation's Capital Area chapter of LLS:
"Overall, approximately 45%, 34% and 6% of FY08 LLS grant funding was committed to research most relevant to leukemia, lymphoma, and myeloma, respectively. This compares with approximately 32% new leukemia cases per year and 41% of blood cancer deaths due to leukemia, 54% new lymphoma cases and 39% deaths due to lymphoma, and 14% new myeloma cases and 20% deaths due to myeloma, when compared to all blood cancer diagnoses and deaths. Approximately 3% of blood cancer diagnoses and 1% of deaths are in children; 7.9% of LLS research funding is specific to pediatric blood cancer research. In addition, the overall research and discoveries on leukemia also has impacts on the pediatric patients. Although Gleevec was developed for adult CML patients, it is now being used for pediatric ALL patients. One of the first peds patients to use Gleevec is from our area being treated at Hopkins.
You can see from the above percentage breakdown that the highest amount of funding is directed to leukemia. The LLS grant review committee selects the projects for funding based on sound science and relevance to improving blood cancer diagnosis and treatments. I will share with you that one of the 13 SCOR Grants that are currently funded is a specifically for pediatric blood cancer. The SCOR grant is our highest level of funding. It is approximately 6.25 million over 5 years. It involves projects from different researchers all working collaboratively on specific topic/approach. We are also working on a new Quality of Life funding initiative for $5 million over three years to research on late affects - this will be primarily peds. In FY08 there was a total of $274 million committed to research funding by LLS. I will have new numbers for FY09 later in the summer."